The Punch on MSN
Scientist urges investment in bone cancer research
A United States-based Nigerian cancer scientist, Rahmon Kanmodi, has called for increased investment in musculoskeletal cancer research across Africa, with particular focus on Nigeria.Kanmodi, a ...
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On ...
VnExpress International on MSN
Father gives up chance at life to treat 9-year-old daughter's cancer
Despite a rapidly growing tumor in his hypopharynx, Nguyen Luong Loi refuses hospitalization and endures severe pain to save every penny for his nine-year-old daughter's chemotherapy.
Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners HOUSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
Among the key speakers was Associate Professor Johnny Ong, Head and Senior Consultant of the Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT) at the National Cancer Cen ...
Adherence to Clinical Practice Guidelines in the management of rare cancers remains inconsistent across Europe despite demonstrably improving patient outcomes, shows an analysis jointly conducted by ...
Tuko News on MSN
Nairobi businesswoman celebrates kind doctor who cleared her loan, saved her from auction
Nairobi businesswoman Damaris Ngina has shared how a doctor’s quiet act of kindness saved her land from auction during the hardest season of her life.
Sydney, Australia Monday, March 16, 2026, 10:00 Hrs [IST] ...
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...
Immutep's ASX-listed stock fell more than 88% on the news that its phase 3 trial TACTI-004 of LAG-3 inhibitor eftilagimod alfa (efti) as a first-line treatment for non-small cell lung cancer (NSCLC) ...
Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results